Cardiovascular Toxicity of Immune Checkpoint Inhibitors: A Guide for Clinicians
Drug Safety · 2023
DOI: 10.1007/s40264-023-01320-5 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift Drug Safety, 2023. Verfasst von Emanuel Raschi und 6 weiteren Autor:innen. Beteiligte Einrichtung: Pharmacology Unit, Department of Medical and Surgical Sciences, Alma Mater Studiorum, University of Bologna, Via Irnerio 48, 40126, Bologna, Italy. e…. Hauptthemen laut MEDLINE: Antineoplastic Agents, Immunological, Myocarditis, Neoplasms. Die Arbeit wurde bisher 46-mal zitiert (Crossref) und nennt 93 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0). Gefördert von: Alma Mater Studiorum - Università di Bologna.
Abstract (Originalsprache)
Immune checkpoint inhibitors (ICIs) have revolutionized the treatment and care of patients with cancer owing to unique features, including the occurrence of the so-called immune-related adverse events (irAEs). A multidisciplinary team, possibly including a cardio-oncology specialist, is warranted to achieve a favorable patient outcome. Cardiovascular toxicity, especially myocarditis, emerged as a life-threatening irAE in the real-word setting, and the European Society of Cardiology has recently published the first guideline on cardio-oncology to increase awareness and promote a standardized approach to tackle this complex multimodal issue, including diagnostic challenges, assessment, treatment, and surveillance of patients with cancer receiving ICIs. In this article, through a question & answer format made up of case vignettes, we offer a clinically oriented overview on the latest advancements of ICI-related cardiovascular toxicity, focusing on myocarditis and associated irAEs (myositis and myasthenia gravis within the so-called overlap syndrome), with the purpose of assisting clinicians and healthcare professionals in daily clinical practice.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- Pharmacology Unit, Department of Medical and Surgical Sciences, Alma Mater Studiorum, University of Bologna, Via Irnerio 48, 40126, Bologna, Italy. emanuel.raschi@unibo.it.
- IRCCS Istituto delle Scienze Neurologiche di Bologna, Bologna, Italy.
- Department of Biomedical and Neuromotor Sciences (DIBINEM), Alma Mater Studiorum, University of Bologna, Bologna, Italy.
- Pharmacology Unit, Department of Medical and Surgical Sciences, Alma Mater Studiorum, University of Bologna, Via Irnerio 48, 40126, Bologna, Italy.
- Medical Oncology, IRCCS Azienda Ospedaliero-Universitaria di Bologna, Bologna, Italy.
- Unit of Heart Failure and Transplantation, IRCCS Azienda Ospedaliero-Universitaria di Bologna, Bologna, Italy.
Förderung
- Alma Mater Studiorum - Università di Bologna
Zitieren
APA
Raschi, E., Rossi, S., De Giglio, A., Fusaroli, M., Burgazzi, F., Rinaldi, R., & Potena, L. (2023). Cardiovascular Toxicity of Immune Checkpoint Inhibitors: A Guide for Clinicians. Drug Safety. https://doi.org/10.1007/s40264-023-01320-5
Vancouver
Raschi E, Rossi S, De Giglio A, Fusaroli M, Burgazzi F, Rinaldi R, et al. Cardiovascular Toxicity of Immune Checkpoint Inhibitors: A Guide for Clinicians. Drug Safety. 2023. doi:10.1007/s40264-023-01320-5
BibTeX
@article{Raschi2023,
author = {Raschi, Emanuel and Rossi, Simone and De Giglio, Andrea and Fusaroli, Michele and Burgazzi, Flavio and Rinaldi, Rita and Potena, Luciano},
title = {Cardiovascular Toxicity of Immune Checkpoint Inhibitors: A Guide for Clinicians},
journal = {Drug Safety},
year = {2023},
doi = {10.1007/s40264-023-01320-5}
}
EUVIMED